Contact Information: Contact: Kelly Cinelli or Veronica Welch CWR 508-222-4802
SpectraScience, Inc. Selects CWR & Partners as Its Public Relations Agency of Record
| Source: CWR & Partners
SAN DIEGO, CA and ATTLEBORO, MA--(Marketwire - January 20, 2010) - CWR & Partners, LLP (CWR)
announced today that it has been named the public relations agency for
SpectraScience, Inc. (OTCBB : SCIE ), a San Diego based medical device
company specializing in spectrophotometry systems.
CWR's mandate and focus will be to leverage its broad base of relationships
within the healthcare national and trade media to raise national and
international awareness for SpectraScience and its optical biopsy systems.
Veronica Welch, Principal at CWR, said, "We think optical biopsy is the
next frontier for cancer screening, offering several advantages over the
incumbent narrowband imaging technology, and SpectraScience has a deep IP
portfolio which will position it as a leader in the space."
SpectraScience holds approximately 60 patents worldwide that have been
issued or are pending on its WavSTAT® Optical Biopsy System and LUMA®
Cervical Imaging Systems. These devices are used to assess tissue quickly
to help determine if it is normal, pre-cancerous, or cancerous. The WavSTAT
and LUMA Systems are approved by the FDA for detecting pre-cancerous and
cancerous tissue in the colon and cervix, respectively. An evaluation of
the WavSTAT for detection of pre-cancers in the throat ("Barrett's
esophagus") is being tested.
"SpectraScience is introducing leading edge technologies to dramatically
improve cancer screening treatment as well as patient outcomes and we are
pleased to help promote them," said Welch. "To date, typical cancer
screening consists of multiple physical biopsies and invasive procedures
that cost more and are frequently inaccurate. We chose to work with
SpectraScience because their technology will not only change the way cancer
screening is done for patients and doctors but it will also save time,
money and lives. We are honored to work for such a cause."
CWR has a ten year history of promoting companies through pro-active media
relations that builds awareness, increases sales and ultimately creates
strong products. CWR has successfully branded companies in several
different markets including medical device, financial, consumer products,
technology and various other industries. CWR clients are frequent experts
seen on CNN, Fox News, ABC, etc.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs,
develops, manufactures and markets spectrophotometry systems capable of
determining whether tissue is normal, pre-cancerous or cancerous without
physically removing tissue from the body. The WavSTAT Optical Biopsy System
uses light to optically scan tissue and provide the physician with an
immediate analysis. With FDA approval for sale in the U.S. and the CE Mark
for the European Union, the WavSTAT System is the first commercially
available product that incorporates this innovative technology for clinical
use. The Company's LUMA imaging technology has received FDA approval for an
optical non-invasive system that is proven to more effectively detect
cervical cancer precursors than conventional methods available in the
market today.
About CWR:
CWR & Partners, LLP, based in Attleboro, MA, was founded in 2001 by public
relations industry veterans Kelly Cinelli and Veronica Welch. Over the past
nine years, the agency has used its public relations skills to garner media
placements for their clients in thousands of publications across the U.S.
and abroad. The company has contacts at all national publications in every
media venue. For more information please call 508-222-4802 or visit
www.cwrpartners.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. These forward-looking
statements involve risks and uncertainties that may cause SpectraScience's
actual results to differ materially from results discussed in
forward-looking statements. Readers are urged to carefully review and
consider the various disclosures made by SpectraScience in this news
release, its most recent Form 10-K and in SpectraScience's other reports
filed with the Securities and Exchange Commission ("SEC") that attempt to
advise interested parties of the risks and factors that may affect
SpectraScience's business. These forward-looking statements are qualified
in their entirety by the cautions and risk factors filed by SpectraScience
in its annual report on Form 10-K and other documents.